allcancercure.com

A novel compound in development by AstraZeneca as an oral tablet for hormone resistant prostate cancer (HRPC), ZD4054, could improve overall survival (OS) in men with metastatic HRPC, according to Phase II data published today in European Urology.[1]
Men with advanced prostate cancer may receive initially effective treatment with hormonal therapies to which the majority of [...]

The Prostate Cancer Foundation (PCF) has made presentations from its 2008 Scientific Retreat available online. The PCF’s annual retreat provides a forum to review advances in prostate cancer research aimed at reducing death and suffering from this prevalent men’s disease. The three-day event was held in October at Incline Village, Nevada, and was attended by [...]

Scientists at Jefferson’s Kimmel Cancer Center in Philadelphia have found that a signaling protein that is key to prostate cancer cell growth is turned on in nearly all recurrent prostate cancers that are resistant to hormone therapy. If the findings hold up, the protein, called Stat5, may be a specific drug target against an extremely [...]

UroToday.com- Frailty in the geriatric field is defined as >3 of the following; unintentional weight loss >10 pounds in the past year, weakness measured by grip strength, slow walking speed, self-reported exhaustion, and low physical activity. Many of these toxicities occur in men receiving androgen-deprivation therapy (ADT) for prostate cancer (CaP). In addition, biomarkers such [...]

UroToday.com- In the November 2007 issue of the Journal of the National Cancer Institute, Dr. Thall and colleagues report on changing chemotherapy regimens based upon patient response and provide statistical modeling to assess outcomes.
They initiated the trial in 1998, prior to the establishment of docetaxel chemotherapy as the first line standard. However, the rationale and [...]

The increase in prostate cancer cases in Nordic countries in recent years is consistent with the increased use of PSA testing over the same period.
Previous studies examining the relationship between the use of prostate-specific antigen (PSA) testing and prostate cancer mortality have been inconsistent.
Rune Kvåle, M.D., of the Cancer Registry of Norway in Oslo and [...]

A mineral diet supplement that lowers the risk of prostate cancer by 50 percent?
While there’s no definitive proof, scientists are intrigued about the connection between prostate cancer risk and selenium, according to the December issue of Mayo Clinic Health Letter.
Selenium is a trace mineral that’s essential to good health. While it’s not an antioxidant, selenium [...]

UroToday.com- One-third of men diagnosed with prostate cancer (CaP) will eventually undergo androgen deprivation therapy (ADT). In the October 2007 issue of the Journal of Urology, Dr. Krupski and associates of Dr. Mark Litwin report that men on ADT experience bone complications of osteoporosis and fractures ten increased health care costs.
The researchers used the MarketScan [...]

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced positive results from a newly completed long-term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). 24 clinical trial sites across the U.S. and 103 unselected subjects participated in the blinded, placebo controlled study.
The study assessed symptom scores and treatment outcome 2 years (range 16-27 months) after a single [...]

African American men face an observable disadvantage versus Caucasian men when it comes to prostate cancer survival. Not only is prostate cancer detected later in African Americans, it is often more aggressive and harder to treat.
Findings on the social and biological factors influencing disparities among African American men are reported today at the American Association [...]